

~DRAFT AGENDA~ October 21, 2019

Day One: Monday, November 4, 2019

8:00 a.m. Registration & Coffee

8:30 a.m. USP Welcome

Fouad Atouf

Vice President, Global Biologics, USP

8:40 a.m. Workshop Overview

Michael De Felippis

Chair, USP Peptide and Oligonucleotide Therapeutics Workshop Steering Committee,

and Chair, USP BIO1 - Peptides and Insulins Expert Committee

8:50 a.m. -10:35 a.m. Session I - Regulatory Considerations

Session Chair: Ved Srivastava

USP Peptide and Oligonucleotide Therapeutics Workshop Steering Committee, and

Member, USP BIO1 - Peptides and Insulins Expert Committee

8:55 a.m. Considerations in Developing Generic Peptide and Oligonucleotide Drug Products

Deyi Zhang CDER, FDA

9:20 a.m. CMC and Regulatory Challenges on Oligonucleotide Drugs

Lawrence Perez CDER, FDA

9:45 a.m. Challenges of Personalized Neoantigen-specific Therapeutic Vaccines

Elena Gubina CBER, FDA

10:10 a.m. CMC, Regulatory, and Quality Strategies for Production of Therapeutic

Oligonucleotides - EU vs. US

Marc Lemaitre
ML Consult LLC

10:35 a.m. Networking Break (20 min)

10:55 a.m. -2:00 p.m. Session II - Analytical and Control Strategies

Session Chair: Marc Lemaitre

USP Peptide and Oligonucleotide Therapeutics Workshop Steering Committee

11:00 a.m. Manufacturing Process and Control Strategy for GalNAc Conjugated siRNAs

Lubo Nechev Alynylam

11:25 a.m. Quality Attributes for siRNA

Robert Duff Amgen



~DRAFT AGENDA~ October 21, 2019

11:50 a.m. Networking Lunch

12:45 p.m. Control Strategies and Analytical Test Methods for Peptide-Conjugates

Thomas Wucherpfennig

Bachem

1:15 p.m. Phase-Appropriate CMC Development for Synthetic Peptides

Tanja Huth Bachem

1:40 p.m. Sessions I and II Panel Discussion/Q&A

2:00 p.m. -3:30 p.m. Session III - Novel Approaches for Characterization

Session Chair: Gerhard Haas

USP Peptide and Oligonucleotide Therapeutics Workshop Steering Committee, and

Member, USP BIO1 – Peptides and Insulins Expert Committee

2:05 p.m. Computational Modeling of the Structure-Function Relationship in RNA

Christina Bergonzo

NIST

2:30 p.m. Analytical Methods for Oligonucleotide Therapeutics

Claus Rentel

Ionis Pharmaceuticals, Inc.

2:55 p.m. Considerations for Biophysical Characterization in Developing Peptide Biologics

Ranajoy Majumdar Eli Lilly and Co.

3:20 p.m. Chiral Purity Testing of Amino Acids by Supercritical Fluid Chromatography

Gareth Murphy

Ipsen

3:45 p.m. Panel Discussion/Q&A

4:00 p.m. -5:30 p.m. Networking Reception



~DRAFT AGENDA~ October 21, 2019

Day Two: Tuesday, November 5, 2019

8:30 a.m. Registration & Coffee

9:00 a.m. -11:50 a.m. Session IV - Impurities and Immunogenicity

Session Chair: Renata Varga

9:05 a.m. Purge-based Risk Assessment for Solvent and Small Molecule Impurities

**Generated During Oligonucleotide Manufacture** 

Jessica Stolee

Biogen

9:30 a.m. Product-related impurity quantitative and qualitative analyses in the context of

**Complex Generic peptide products** 

Liqing Gu

SGS West Chester

9:55 a.m. New Dogs/Old Tricks: Methods for Assessing the Immunogenicity of Peptide

**Drugs and Their Impurities** 

Anne De Groot *EpiVax, Inc.* 

10:30 a.m. Panel Discussion / Q&A

10:45 a.m. Networking Break (20 min)

11:05 a.m. - 2:05 p.m. Session V - Novel Therapeutics and Analytical Strategies

Session Chair: Michael De Felippis

Chair, USP BIO1 – Peptides and Insulins Expert Committee

11:10 a.m. Tailor-made therapeutic peptides for accelerated clinical development

Stefania Pfeiffer-Marek

Sanofi-Aventis Deutschland GmbH

11:35 a.m. Peptide sameness: Challenges and regulatory requirements

Walter Cabri Fresenius Kabi

12:00 p.m. Networking Lunch

1:00 p.m. Discrimination of Strongly related Peptides and Detection of Peptide Aggregation

by NMR

Edwin Kellenbach
Aspen Pharmacare

1:25 p.m. Cell Based Potency Assays for Peptides: Challenges and Strategies

Sabrina Rüggeberg

Sanofi



~DRAFT AGENDA~ October 21, 2019

1:50 p.m. Panel Discussion / Q&A

2:05 p.m. Workshop Wrap-up

Michael De Felippis

Chair, USP BIO1 – Peptides and Insulins Expert Committee

2:15 p.m. Adjourn